Overview

Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study aims to prove that at a dose of 1 mg Haloperidol possesses a high success rate in controlling established postoperative nausea and vomiting (PONV) in the first 24 hours following administration similar to the standard of care ondansetron 4 mg.
Phase:
Phase 4
Details
Lead Sponsor:
American University of Beirut Medical Center
Treatments:
Haloperidol
Haloperidol decanoate
Ondansetron